MNTA  Momenta Pharmaceuticals Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+0.075 (+0.521%)

Company Metrics

  • P/E 13.83
  • P/S 10.152
  • P/B 3.048
  • EPS -1.34
  • Cash ROIC -52.09%
  • Cash Ratio 9.03
  • Dividend 0 / 0%
  • Avg. Vol. 586,392.00
  • Shares 68.96M
  • Market Cap. 998.15M

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Motley Fool - Oct 11, 2016
Before then, it seems likely Momenta will try and partner M923 (again). Last month, Momenta announced that it will regain rights to the drug from Shire.
Momenta Pharmaceuticals (MNTA) Stock Surges, Barclays Upgrades -
Momenta Pharmaceuticals (MNTA) Surges on Barclays Upgrade - Economic Calendar
Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales
Motley Fool - Nov 4, 2016
Momenta recorded $23.3 million in product revenues from its partner Novartis' (NYSE:NVS) sale of Glatopa, their generic version of Teva Pharmaceuticals' (NYSE:TEVA) once-daily multiple sclerosis drug Copaxone. That's an increase of over $2 million ...
Momenta and Mylan Initiate Phase 1 Clinical Trial for M834, a Proposed ... - PR Newswire (press release)
Prudential Financial Inc. Sells 41150 Shares of Momenta Pharmaceuticals Inc ...
Sports Perspectives - Jan 23, 2017
Momenta Pharmaceuticals logo Prudential Financial Inc. reduced its stake in Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) by 27.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission.
The Alambic Investment Management LP Decreases Stake in Momenta ... - DailyQuint
Tocqueville Asset Management L.P. Has $3417000 Stake in Momenta ... - Community Financial News
Momenta Pharmaceuticals Inc. Shed a Third of Its Value in February -- Here's Why
Motley Fool - Mar 4, 2016
What: Shares of Momenta Pharmaceuticals (NASDAQ:MNTA), a biopharmaceutical company focused on the development of generic and biosimilar drugs for oncology and autoimmune diseases, shed 33% of their value in February, based on data from S&P ...
What The Charts Are Saying About Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)
Marion Business Daily - 8 hours ago
In looking at the Value Composite score for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), we see that the firm has a rank of 87.
Momenta Pharmaceuticals Inc. (MNTA) Plunges 6.83% on January 17 - Jan 17, 2017
Momenta Pharmaceuticals Inc. (MNTA) had a rough trading day for Tuesday January 17 as shares tumbled 6.83%, or a loss of $-1.1 per share, to close at $15.00.
Why Momenta Pharmaceuticals, Inc. Earned a Lower Price Today
Motley Fool - Feb 18, 2016
What: Momenta Pharmaceuticals (NASDAQ:MNTA) is down 11% at 12:00 p.m. EST Thursday after releasing fourth quarter earnings this morning.
Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?
Motley Fool - Aug 9, 2016
While the report included sales of Momenta's and partner Novartis AG's (NYSE:NVS) Glatopa, the generic version of Teva Pharmaceutical Industries' (NYSE:TEVA) once-daily Copaxone, investors should focus on the potential approval of the generic ...
A Somewhat Murky Outlook For Momenta Pharmaceuticals
Seeking Alpha - Dec 28, 2016
Although I have made some good gains from Momenta Pharmaceuticals over the past few months, it is one of the murkiest companies I follow in the biotech space.
Stock Returns: Momenta Pharmaceuticals Inc (NASDAQ:MNTA) is Beating OncoMed ... - CML News
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Sales Predicted At $298.23 - Investor Newswire
Momenta Pharmaceuticals: Waiting for Fewer Injections
Motley Fool - May 9, 2016
The Motley Fool recommends Momenta Pharmaceuticals, Mylan, and Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days.